Evidence map›Paper›PMID 38444369›Full record

ArticleEmerging microbes & infections2024

Effective and targeted latency reversal in CD4

Minh Ha Ngo, Joshua Pankrac, Ryan C Y Ho, Emmanuel Ndashimye, Rahul Pawa, Renata Ceccacci, Tsigereda Biru, Abayomi S Olabode, Katja Klein, Yue Li and 16 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.8field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Fast pH-Driven Solubilization Method of Realgar (AsAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 8 institutions in 5 countries.

Minh Ha NgoDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Joshua PankracDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Ryan C Y HoDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Emmanuel NdashimyeDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Rahul PawaDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Renata CeccacciDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Tsigereda BiruDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Abayomi S OlabodeDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Katja KleinDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Yue LiDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Colin KovacsMaple Leaf Medical Clinic and Division of Infectious Diseases, Department of Medicine, University of Toronto, Toronto, Canada.
Robert AssadSpecial Immunology Unit and Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Jeffrey M JacobsonSpecial Immunology Unit and Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
David H CanadaySpecial Immunology Unit and Division of Infectious Diseases, Department of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Stephen TomusangeRakai Health Sciences Program, Kalisizo, Uganda.
Samiri JamiruRakai Health Sciences Program, Kalisizo, Uganda.
Aggrey AnokRakai Health Sciences Program, Kalisizo, Uganda.
Taddeo KityamuweesiRakai Health Sciences Program, Kalisizo, Uganda.
Paul BuuleRakai Health Sciences Program, Kalisizo, Uganda.
Ronald M GaliwangoRakai Health Sciences Program, Kalisizo, Uganda.
Steven J ReynoldsRakai Health Sciences Program, Kalisizo, Uganda.
Thomas C QuinnDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew D ReddDivision of Infectious Diseases, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Jessica L ProdgerDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Jamie F S MannDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Eric J ArtsDepartment of Microbiology and Immunology, University of Western Ontario, London, Canada.
Western University · CARakai Health Sciences Program · UGCase Western Reserve University · USNational Institute of Allergy and Infectious Diseases · USNational Institutes of Health · USUniversity of Bristol · GBUniversity of Toronto · CAVietnam National University of Agriculture · VN

Funding

International Center for Excellence in Research (ICER) in Uganda: Impact of ARVsZIAAI001040 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REYNOLDS, STEVEN · 2009 to 2025
$23.5M
International Studies of the Acquired Immune Deficiency Syndrome (AIDS)ZIAAI000361 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI REDD, ANDREW · 2009 to 2025
$15.8M
Impact of HIV-1 Fitness on Disease ProgressionR01AI049170 · NIAID · UNIVERSITY OF WESTERN ONTARIO · PI ARTS, ERIC J · 2002 to 2024
$6.8M
HIV-1 Fitness and RecombinationR56AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2012 to 2012
$400k
Impact of HIV-1 Fitness on Disease ProgressionR21AI049170 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI ARTS, ERIC J · 2001 to 2001
$265k
NIAID NIH HHS R01 AI049170NIAID NIH HHS R21 AI049170NIAID NIH HHS R56 AI049170
6 · The paper itself

Abstract

To date, an affordable, effective treatment for an HIV-1 cure remains only a concept with most "latency reversal" agents (LRAs) lacking specificity for the latent HIV-1 reservoir and failing in early clinical trials. We assessed HIV-1 latency reversal using a multivalent HIV-1-derived virus-like particle (HLP) to treat samples from 32 people living with HIV-1 (PLWH) in Uganda, US and Canada who initiated combined antiretroviral therapy (cART) during chronic infection. Even after 5-20 years on stable cART, HLP could target CD4

Indexed as

HIV-1HIV InfectionsCanadaCD4-Positive T-LymphocytesHumansVirus LatencyCD4+ T cellschronic HIV-1 infectionHIV-1 cureHIV-1 latency reversallatency reversal agentreplication-competent latent reservoirvirus-like particles

Identifiers

PMID38444369
PMCPMC10967673
OpenAlexW4392511075

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.